087010.KQ
Peptron, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 146,600.00
−6.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.0B | 5.6B | 3.2B | 3.3B | 5.8B |
| Cost of Revenue | 6.6B | 4.9B | 2.0B | 5.1B | 7.3B |
| Gross Profit | (887.3M) | 760.0M | 1.1B | (1.8B) | (1.5B) |
| Operating Expenses | |||||
| R&D Expense | 17.7B | 15.2B | 12.1B | 11.4B | 13.4B |
| SG&A Expense | 3.1B | 3.8B | 2.9B | 5.2B | 4.9B |
| General & Admin Expense | (81.1M) | 2.4B | 1.7B | 1.5B | 1.3B |
| Selling & Marketing Expense | 1.0B | 1.4B | 1.2B | 1.3B | 1.4B |
| Other Expenses | 3.9B | 3.0B | 2.6B | (1.2B) | (3.9B) |
| Total Operating Expenses | 24.8B | 22.0B | 17.6B | 15.5B | 14.3B |
| Cost and Expenses | 31.7B | 26.9B | 19.7B | 20.6B | 21.6B |
| Operating Income (EBIT) | (25.7B) | (21.3B) | (16.5B) | (15.6B) | (15.8B) |
| Non-Operating | |||||
| Interest Income | 4.6B | 4.4B | 671.8M | 242.1M | 422.6M |
| Interest Expense | 2.5B | 1.3B | 472.9M | 396.0M | 279.7M |
| Net Interest Income | 2.1B | 3.1B | 198.9M | (154.0M) | 142.9M |
| Other Non-Op Income/Expense | 4.5B | 6.9B | (5.1B) | (337.9M) | 714.4M |
| Non-Operating Income (excl Interest) | (5.8B) | — | 4.6B | (58.1M) | (439.3M) |
| EBT (Pre-Tax Income) | (21.1B) | (14.3B) | (21.6B) | (15.9B) | (15.1B) |
| Income Tax Expense | (570.6M) | (503.0M) | 414.4M | (18.9M) | (4.2M) |
| Bottom Line | |||||
| Net Income | (20.5B) | (13.8B) | (22.0B) | (15.9B) | (15.1B) |
| Earnings from Cont. Ops | (20.5B) | (13.8B) | (22.0B) | (15.9B) | (15.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (20.5B) | (13.8B) | (22.0B) | (15.9B) | (15.1B) |
| Per Share | |||||
| Basic EPS | (₩883) | (₩593) | (₩1,061) | (₩774) | (₩730) |
| Diluted EPS | (₩883) | (₩593) | (₩1,061) | (₩774) | (₩730) |
| Revenue Per Share | ₩258 | ₩242 | ₩152 | ₩162 | ₩282 |
| Shares | |||||
| Basic Shares Outstanding | 23.2M | 23.3M | 20.8M | 20.6M | 20.6M |
| Diluted Shares Outstanding | 23.2M | 23.3M | 20.8M | 20.6M | 20.6M |
| Profitability Metrics | |||||
| EBITDA | (29.5B) | (18.5B) | (18.5B) | (12.7B) | (9.7B) |
| D&A | 3.0B | 2.7B | 2.7B | 2.9B | 5.1B |
| EBIT | (32.6B) | (21.3B) | (21.1B) | (15.5B) | (14.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026